Pegylated Liposomal Doxorubicin (Caelyx®) in Metastatic Breast Cancer: A Community-Based Observation Study

Publisher： Karger

E-ISSN： 1423-0232|72|3-4|147-151

ISSN： 0030-2414

Source： Oncology, Vol.72, Iss.3-4, 2007-12, pp. : 147-151

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer

By  

Oncology, Vol. 76, Iss. 4, 2009-03 ,pp. : 275-285

Karger

Access to resources Recommend Favorite

Pegylated Liposomal Doxorubicin with Vinorelbine in Metastatic Breast Carcinoma

By  

Oncology, Vol. 63, Iss. 1, 2002-08 ,pp. : 23-30

Karger

Access to resources Recommend Favorite

Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer After First-Line Treatment Failure

By  

Oncology Research and Treatment, Vol. 27, Iss. 5, 2004-10 ,pp. : 441-446

Karger

Access to resources Recommend Favorite

Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 32, Iss. 1-2, 2009-01 ,pp. : 18-24

Karger

Access to resources Recommend Favorite

Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 210-214

Karger

Access to resources Recommend Favorite